18th September 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Professor Tom Powles.
Read more16th September 2020
Results from a phase I clinical trial led by Professor Peter Szlosarek were recently published in JTO Clinical and Research Reports. The trial was investigating the safety and efficacy of a new drug combination for the treatment of mesothelioma. We spoke to Professor Szlosarek to find out more about the trial, and how the drug combination may be able to help patients with mesothelioma.
Read more15th September 2020
Professor John Gribben, Lead for the Centre for Haemato-Oncology at Barts Cancer Institute and Consultant Haematologist at Barts Health NHS Trust, is part of a new BBC Two series called The Diagnosis Detectives. Professor Gribben is one of a panel of 12 of the UK’s leading medical experts who have been assembled to diagnose patients with life-changing symptoms that have puzzled other doctors and remained undiagnosed.
Read more14th September 2020
Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution. The information gained from using this model may be able to be used to predict whether immunotherapy is likely to be effective for a patient’s cancer, helping to guide treatment decisions.
Read more9th September 2020
A new study has identified molecular characteristics in ‘normal-looking’ tissues surrounding breast tumours that may indicate whether breast cancer is likely to return following surgical removal of the tumour.
Read more2nd September 2020
Researchers have developed a computation model that can reconstruct the evolutionary history of cancer. By unravelling the genetic complexity of a tumour, the tool can be used to better understand how the cancer has developed and may help to guide treatment strategies in the future.
Read more